ClinVar Miner

Submissions for variant NM_000352.6(ABCC8):c.928G>A (p.Asp310Asn)

gnomAD frequency: 0.00001  dbSNP: rs769569410
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Athena Diagnostics RCV000710397 SCV000840609 likely pathogenic not provided 2018-04-20 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000710397 SCV001394775 likely pathogenic not provided 2023-09-22 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 310 of the ABCC8 protein (p.Asp310Asn). This variant is present in population databases (rs769569410, gnomAD 0.003%). This missense change has been observed in individual(s) with congenital hyperinsulinism and type 2 diabetes (PMID: 16429405, 18596924, 27188453, 33046911). ClinVar contains an entry for this variant (Variation ID: 585352). Experimental studies have shown that this missense change affects ABCC8 function (PMID: 18596924, 20427569). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCC8 protein function. This variant disrupts the p.Asp310 amino acid residue in ABCC8. Other variant(s) that disrupt this residue have been observed in individuals with ABCC8-related conditions (PMID: 17236890; Invitae), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
DASA RCV002255099 SCV002526400 likely pathogenic Type 2 diabetes mellitus 2022-06-10 criteria provided, single submitter clinical testing The c.928G>A;p.(Asp310Asn) missense change has been observed in affected individual(s) and ClinVar contains an entry for this variant (Clinvar ID: 585352; PMID: 27908292; 27188453; 23275527; 21536946; 20427569; 18596924) - PS4.Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product (PMID: 20427569) - PS3_supporting. The variant is present at low allele frequencies population databases (rs769569410– gnomAD 0.00006569%; ABraOM 0.000427 frequency - http://abraom.ib.usp.br/) -PM2_supporting. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is Likely Pathogenic
Fulgent Genetics, Fulgent Genetics RCV002499280 SCV002814031 likely pathogenic Diabetes mellitus, transient neonatal, 2; Hyperinsulinemic hypoglycemia, familial, 1; Leucine-induced hypoglycemia; Type 2 diabetes mellitus; Diabetes mellitus, permanent neonatal 3 2022-01-04 criteria provided, single submitter clinical testing
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV003321726 SCV004026573 likely pathogenic Hyperinsulinemic hypoglycemia, familial, 1 2023-08-16 criteria provided, single submitter curation The p.Asp310Asn variant in ABCC8 has been previously reported in 3 individuals with hyperinsulinemic hypoglycemia (PMID: 16429405, 17236890, 27908292) and has been seen in 0.006% (2/34590) of Latino/Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP: rs769569410). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID: 585352) and has been interpreted as likely pathogenic by Fulgent Genetics, DASA, Natera Inc, Athena Diagnostics Inc, and Invitae. Of the 3 affected individuals, 1 was a compound heterozygote that carried a reported likely pathogenic variants in trans, which increases the likelihood that the p.Asp310Asn variant is pathogenic (PMID: 17236890). In vitro functional studies provide some evidence that the p.Asp310Asn variant may slightly impact protein function (PMID: 18596924, 20427569). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive hyperinsulinemic hypoglycemia. ACMG/AMP Criteria applied: PM3, PP3, PM2, PS3_supporting (Richards 2015).
Baylor Genetics RCV002255099 SCV004196313 likely pathogenic Type 2 diabetes mellitus 2024-03-22 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV004782524 SCV005394523 likely pathogenic Familial hyperinsulinism 2024-09-12 criteria provided, single submitter clinical testing Variant summary: ABCC8 c.928G>A (p.Asp310Asn) results in a conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 250942 control chromosomes (gnomAD). c.928G>A has been reported in the literature in individuals affected with Familial Hyperinsulinism (Fernandez-Marmiesse2006, Pinney_2008, Martnez_2016, Salomon-Estebanez_2016, Motte-Signoret_2022). These data indicate that the variant is likely to be associated with disease. At least one publication reports this variant affects protein function (Pinney_JCI_2008). The following publications have been ascertained in the context of this evaluation (PMID: 31464105, 16429405, 21536946, 27188453, 36144251, 18596924, 27908292, 23275527). ClinVar contains an entry for this variant (Variation ID: 585352). Based on the evidence outlined above, the variant was classified as likely pathogenic.
Juno Genomics, Hangzhou Juno Genomics, Inc RCV003321726 SCV005416373 likely pathogenic Hyperinsulinemic hypoglycemia, familial, 1 criteria provided, single submitter clinical testing PM2_Supporting+PP3_Moderate+PS4_Moderate+PP4
Natera, Inc. RCV001825411 SCV002078269 likely pathogenic Hereditary hyperinsulinism 2021-01-25 no assertion criteria provided clinical testing
PreventionGenetics, part of Exact Sciences RCV004735763 SCV005361695 pathogenic ABCC8-related disorder 2024-04-16 no assertion criteria provided clinical testing The ABCC8 c.928G>A variant is predicted to result in the amino acid substitution p.Asp310Asn. This variant has been reported in the heterozygous and compound heterozygous states in multiple individuals with congenital hyperinsulinism (see for example, Table 1, Fernandez-Marmiesse et al. 2006. PubMed ID: 16429405; Table 2, Martínez et al. 2016. PubMed ID: 27188453; Motte-Signoret et al. 2022. PubMed ID: 36144251). Functional studies have shown that this variant affects ABCC8 surface expression and function (Table 4, Pinney et al. 2008. PubMed ID: 18596924; Figure 5, Yan et al. 2010. PubMed ID: 20427569). This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD. An alternative substitution affecting the same amino acid (p.Asp310Val) has been reported in association with hyperinsulinism (Table 2, Hardy et al. 2007. PubMed ID: 17236890). This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.